Puriblood Medical Co., Ltd. (TPEX:6847)
Taiwan · Delayed Price · Currency is TWD 75.70
+5.40 (7.68%)
Jun 25, 2026, 1:54 PM CST
Puriblood Medical Revenue
In the year 2025, Puriblood Medical had annual revenue of 82.34M TWD, down -25.61%. Puriblood Medical had revenue of 42.09M in the half year ending December 31, 2025, a decrease of -54.74%.
Revenue
82.34M
Revenue Growth
-25.61%
P/S Ratio
13.08
Revenue / Employee
2.17M
Employees
38
Market Cap
1.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 82.34M | -28.34M | -25.61% |
| Dec 31, 2024 | 110.67M | -14.60M | -11.65% |
| Dec 31, 2023 | 125.27M | -12.17M | -8.86% |
| Dec 31, 2022 | 137.44M | 82.86M | 151.79% |
| Dec 31, 2021 | 54.59M | 15.94M | 41.25% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BIONET | 1.26B |
| DIVA Laboratories | 884.63M |
| Genetics Generation Advancement | 609.13M |
| Kim Forest Enterprise | 570.49M |
| Sofiva Genomics | 382.82M |
| Welgene Biotech | 381.82M |
| Pharmigene | 199.89M |